Evidence Class IIb — may be considered but benefit unproven
Etanercept emerging evidence
Targets TNF-alpha — key upstream cytokine in keratinocyte apoptosis
Single SC 50 mg dose associated with faster re-epithelialization in Chinese RCT
International validation ongoing — promising Class IIa evidence
Multidisciplinary care model
Burn unit co-management associated with best outcomes
Ophthalmology involvement within 24 hours reduces chronic ocular sequelae
Pharmacogenomic counseling and HLA testing before discharge for at-risk populations
Patient Discharge Instructions
copy discharge instructions
Medication allergy warning
The medication that caused your skin reaction has been permanently documented as a severe allergy in your medical record
Never take this medication or any chemically related medication again
Obtain a medical alert bracelet or wallet card listing the specific drug to avoid
Tell every doctor, dentist, pharmacist, and emergency provider about this allergy at every visit
Skin and wound recovery
Your skin will continue to heal over the coming 1–3 weeks
Keep affected areas clean and protected from sun exposure
Use sunscreen SPF 30 or higher on all areas that had skin involvement
Photosensitivity may persist for months — avoid prolonged sun exposure
Skin colour changes (darker or lighter areas) are expected and may last months to years
Eye care instructions
Attend all scheduled ophthalmology appointments — chronic eye problems occur in up to 65% of survivors
Use all prescribed eye drops exactly as directed
Return to emergency immediately for sudden vision change, severe eye pain, or new redness
Return to emergency department immediately for
Any new blistering, skin peeling, or painful rash — especially after starting a new medication
Mouth sores, eye redness or pain, or painful urination that develops after any new drug
Fever with a new rash of any kind
Difficulty breathing, chest tightness, or new cough
Severe eye pain, sudden vision change, or inability to open eyes
Ongoing follow-up appointments
Dermatology within 2–4 weeks of discharge
Ophthalmology — ongoing follow-up for at least 1 year
Family doctor within 1 week for medication review and wound check
Urology or gynecology if genital areas were involved
Mental health support — depression, anxiety, and PTSD are common after this illness
Psychological support
Experiencing stress, anxiety, or flashbacks after this illness is common and expected
Resources available: your family doctor can refer to counselling or psychiatry
Support groups for SJS/TEN survivors exist online and may be helpful
Pharmacogenomic considerations
Ask your doctor about genetic testing (HLA typing) before starting new anticonvulsant or allopurinol therapy
HLA-B15:02 testing recommended before carbamazepine if you have Southeast Asian ancestry
HLA-B58:01 testing recommended before allopurinol if you have Asian or African ancestry
References
Guidelines and key sources
Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe Cutaneous Adverse Reactions to Drugs. Lancet. 2017. PMID 28476287
Comprehensive review of SJS/TEN pathogenesis, diagnosis, and management
Lee EY, Knox C, Phillips EJ. Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatology. 2023
Incidence and antibiotic-associated epidemiology
Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clinical Reviews in Allergy and Immunology. 2018. PMID 29188475
Pathophysiology and clinical management review
van Nispen C, Long B, Koyfman A. High Risk and Low Prevalence Diseases: Stevens Johnson Syndrome and Toxic Epidermal Necrolysis. American Journal of Emergency Medicine. 2024. PMID 38631147
Emergency medicine-focused management review
Maverakis E, Wang EA, Shinkai K, et al. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group. JAMA Dermatology. 2017
NIH consensus guidelines for SJS/TEN evaluation and reporting
Jacobsen A, Olabi B, Langley A, et al. Systemic Interventions for Treatment of Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and SJS/TEN Overlap Syndrome. Cochrane Database of Systematic Reviews. 2022
Cochrane review — no mortality benefit from IVIG; limited evidence for all systemic agents
Ingen-Housz-Oro S, Matei I, Gaillet A, et al. Diagnosing and Managing Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Adults: Review of Evidence 2017-2023. Journal of Investigative Dermatology. 2025. PMID 40019457
Current best practice synthesis including cyclosporine and etanercept evidence
Kridin K, Bruggen MC, Chua SL, et al. Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Pan-European Multicenter Study. JAMA Dermatology. 2021
Real-world treatment outcomes across European centers
Koh HK, Fook-Chong SMC, Lee HY. Improvement of Mortality Prognostication in Patients With Epidermal Necrolysis: Proposed Revision of SCORTEN (Re-SCORTEN). JAMA Dermatology. 2022
SCORTEN validation and revised scoring with inflammatory markers
Chiu HY, Chiu YM. Risk of Cardiovascular Morbidity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Survivors. JAMA Dermatology. 2025
Sotozono C, Ueta M. Updates on the Ocular Manifestations and Treatment of SJS/TEN. Allergology International. 2025. PMID 40500649
Current ocular management including amniotic membrane and betamethasone drops
Martinez Villarreal JD, Cardenas-de la Garza JA, Ionescu MA, et al. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Current Management and Innovative Therapies. International Journal of Dermatology. 2025. PMID 40231717
Emerging therapies including etanercept evidence
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.